Endocrine Abstracts

Background: Chemerin is a recently identified adipocyte-secreted signalling molecule (adipokine) that regulates adipocyte differentiation, metabolism, and inflammation through activation of the cognate receptor Chemokine-Like Receptor 1 (CMKLR1). Circulating chemerin levels are increased in obese patients as well as in patients with inflammatory bowel disease (IBD) such as Crohn’s disease and ulcerative colitis. Increased white adipose tissue mass (WAT) and resultant chan...

Objective: NPY2R is a G-protein-coupled receptor which is highly expressed in orexigenic NPY/AGRP neurons within the arcuate nucleus, a major integrator of appetite control in the hypothalamus. Genetic evidence coming from animal and association studies, has identified NPY2R as a candidate gene for obesity. Therefore we have designed an extensive mutation and CNV-analysis investigating the prevalence of genetic and structural variation in NPY2R.Design an...

Whether high glycaemic index/glycaemic load (GI/GL) diets increase low-grade inflammation leading to changes in body composition and risk for chronic illness remains uncertain. We recently completed a randomised, double-blind study comparing the effects of a 45 g whey protein supplement (PRO) and an isocaloric maltodextrin supplement (CHO) on bone density and body composition in older adults. The study afforded an opportunity to evaluate the impact of a calibrated increase in ...

While female fertility is known to be sensitive to conditions of low body fuel reserves, the reproductive consequences of persistent energy excess remain ill defined. Yet, the pandemic proportions of obesity, and its potential impact on the gonadotropic axis, call for a better understanding of this phenomenon. Alike, the influence of ovarian hormones on the pathophysiology of obesity and its complications merits further investigation. In this work, we aimed to elucidate the me...

Introduction: Cross-sex hormone therapy is part of the treatment of individuals with gender dysphoria and affects several factors such as body composition and thereby cardiovascular risk. However, little is known about the specific effects on body weight and fat percentage in the first year of treatment.Aim: The aim of this study is to examine the effects of cross-sex hormones on body weight and total fat percentage during the first year of treatment.</p...

Lowered testosterone levels may be observed in up to 50% of ageing men with type 2 diabetes (T2D). Testosterone replacement therapy (TRT) increases lean body mass in men with lowered testosterone levels and T2D, but the effect of TRT on glucose metabolism has not been evaluated by euglycemic hyperinsulinemic clamp.We used gold standard methods to evaluate the effect of TRT on body composition, insulin sensitivity, and oxidative metabolism in men with T2D...

Context: Studies suggest that 25–40% of men with type 2 diabetes mellitus (T2DM) have hypogonadism. Other studies have estimated that 40–50% of men with T2DM have erectile dysfunction (ED). Some guidelines suggest routine measurements of testosterone in all patients with T2DM.Objectives: To estimate the prevalence of hypogonadism in adult male patients with type 2 diabetes mellitus and symptomatic erectile dysfunction.Met...

Objectives: Diabetes and obesity – Translational cardiovascular and obesityData regarding the prevalence of eating disorders (ED) and their influence on clinical outcomes among patients with type 2 diabetes (T2DM) are scarce. Our aim is to investigate the frequency of positive screening for ED and, specifically binge eating disorder (BED), in a T2DM sample. To analyse whether there are any differences among T2DM subjects with a positive screening for ED or BED.<p clas...